Aspen Labs Mexico – Carlos Abelleyra Cordero, CEO Spanish LATAM
Aspen Labs wants Latin America to be the third pillar of success for the company, and is doing it in a different way. The CEO for Spanish Latin America discusses…
Ranked as the ninth largest generic company in the world, South African-based Aspen is a supplier of branded and generic pharmaceuticals in more than 150 countries across the world and of consumer and nutritional products in selected territories. The Group currently has 50 business units , 26 manufacturing facilities at 18 sites on 6 continents and approximately 8200 employees. In Latin America Aspen supplies a range of quality affordable products through its affiliate companies in Mexico, Argentina, Brazil and Venezuela as well as across the rest of Latin America in countries such as Chile, Colombia, Ecuador and the Carricam territories. Aspen sees Latin America as one of its key strategic regions with significant growth potential within the Group, and continues to seek opportunities to establish a greater presence in other Latin American countries.
Contact Details
Aspen Labs, S.A. De C.V.
Av. Insurgentes Sur 1685
Col. Guadalupe Inn, Del. Alvaro Obregón
C.P. 01020 México D.F.
Tel: +52 (55) 9126 0860
Website: aspenlabs.com.mx
Aspen Labs wants Latin America to be the third pillar of success for the company, and is doing it in a different way. The CEO for Spanish Latin America discusses…
The Aspen Group identified Latin America as a “large developing market where it can leverage its substantial intellectual property portfolio and manufacturing infrastructure”. What was the original strategy behind getting…
It’s been one year since you were appointed as Federal Commissioner of COFEPRIS in March 2011. What have been the biggest challenges you’ve faced within this time? The biggest challenge…
Can you tell us a little about the history of Medix and about the company itself? Medix is a 100% Mexican company created in 1956, and our major strength is…
Apotex has increased production, launched 16 new products last March, and grown significantly in the market. What would you say has been the biggest change in the market over the…
The last time we interviewed you was in 2008. Please can you tell our readers a little bit more about Liomont’s growth drivers and changes over these last four years?…
When we saw you in 2008 we had read a little bit about the major milestones in the company, how your grandfather came to Mexico in the 1950s and how…
Please can you tell our readers a little bit more about the history of Stendhal, and its major milestones along the way since its takeover in 1997? Stendhal is a…
Carlos Garcia said in December 2009 that 6-8% of Novartis’ annual revenue comes from Latin America, and that the area is “one of the main growth engines for the company”.…
Big news last year; Takeda bought Nycomed in what has been seen as a game changing acquisition for the pharma world. How have you seen this acquisition affect Nycomed’s Latin…
The Mexican government has been fairly pro-active about promoting good practice such as the new drug registration process that helped eliminate drugs from the Mexican market that didn’t fulfill regulatory…
There have been quite a few regulatory changes in the last few years such as the new drug registration process and the suppression of the local plant rule. COFEPRIS has…
This is your 3rd interview with Focus Reports. What would you say has been the biggest change that has shaped the pharmaceutical industry since we last interviewed you in 2008?…
This is your third interview with Focus Reports. In 2004 and 2008 you were Director of AMIIF, before that you were Director of ANAFAM, and now we’re delighted to be…
See our Cookie Privacy Policy Here
